

Surprisingly Low HPV Vaccination Rates Explained by Experts; CBCD Reviews a Report

Experts blame the way Gardasil was introduced to the medical community for the low vaccination rates. (1)

ROCHESTER, NEW YORK, UNITED STATES OF AMERICA, July 15, 2015 /EINPresswire.com/ --

“Infected with the HPV virus? The CBCD recommends taking [Gene-Eden-VIR](#) or [Novirin](#).” - Greg Bennett, CBCD

National Public Radio (NPR) claims that the medical community made a huge mistake in how it chose to push for HPV vaccination. “Part of the problem is that the original testing on the vaccine was done only on girls, and its 2006 approval was for girls only; approval for boys didn’t come until 2009, and it wasn’t added to the list of vaccines for boys until 2011.” (1) Because the vaccine was originally only approved for girls, “encouraged arguments that the vaccine, which protects against a sexually-transmitted infection leading to cancer ... (because it)...would introduce sexuality, that would inappropriately introduce promiscuity.” (1) In simple terms, the reason for the failure is the association between the vaccine and irresponsible sexual behavior by teenage girls.

However, the Center for the Biology of Chronic Disease (CBCD) believes that morality is only one issue that may have caused a failure in acceptance of the vaccine. The Center believes that another issue is safety.

For example, over a ten year period, there were 8,228 reports of side effects associated with the HPV vaccine, “almost more than all other routine jabs put together.” (2) Importantly, “more than a quarter of these reports were classed as 'serious', a category that includes symptoms severe enough to require hospital treatment or even be life-threatening.” (2) Descriptions from those who received the vaccine explained how, after

vaccination, they experienced “fits, extreme tiredness and even been left wheelchair-bound after being vaccinated in their early teens. In some cases, the girls started to feel ill on



weeks later.” (2)

The CBCD believes, therefore, that the low acceptance rates are a result of parental concerns over both morality and safety.

“Parents are not being given enough information about potential side-effects of the vaccine ... girls who fall ill after vaccination are not being taken seriously by GPs (General Physicians) when parents suggest the illness could be vaccine-related. Jackie Fletcher, of pressure group Jabs, said: 'Previously fit and healthy young girls have developed seizures or viral fatigue, some have lost the ability to walk. And years on, some have still not recovered.'” (2)

The Center for the Biology of Chronic Disease (CBCD) points out that while many governments have approved the HPV vaccine, still there is a minority of experts who urge caution. For example, Dr. Uzi Beller, chief professor of obstetrics/gynecology at Shaare Zedek Medical Center in Israel, urged the medical community to be cautious in regards to HPV vaccination. “I want to see fundamental studies proving efficacy, and they do not exist.” (3)

The vaccines, Beller said, “were tested on mostly white women attending colleges and university - mostly from developed countries and healthy. The data were based on a relatively short term follow-up period. What is known does not yet justify widespread vaccination of healthy girls (2).” In addition, Dr. Beller said that “there is no evidence that prophylactic (preventative) vaccination against HPV types 16 and 18 reduces the incidence of cervical cancer.” As the vaccine costs \$100 to \$360 for three doses in wealthy countries, it is completely out of the reach of developing countries, where an effective vaccine would be most urgently needed (3).”

The Jerusalem Post report concluded that “pediatricians are important advocates for preventive medicine, but they may know little about HPV infection and cervical and other HPV-related cancers. Obstetricians / Gynecologists know about HPV and cervical cancer prevention, but they often know little about vaccines and immunization delivery (3).”

Click to learn more about [HPV symptoms](#).

The CBCD recommends that HPV infected individuals consider taking Gene-Eden-VIR or Novirin. A recent post marketing clinical study published in the peer reviewed, medical journal Pharmacology & Pharmacy, in a special edition on Advances in Antiviral Drugs on August 12, 2013 showed that the formula of Novirin and Gene-Eden-VIR reduced HPV symptoms and was safe and effective (4).

The formula of Novirin and Gene-Eden-VIR was tested by Hanan Polansky and Edan Itzkovitz from the CBCD in two clinical studies that followed FDA guidelines. The studies showed that the Novirin and Gene-Eden-VIR formula is effective against the HPV and other viruses. The clinical studies were published in the peer reviewed, medical journal Pharmacology & Pharmacy, the first, in a special edition on Advances in Antiviral Drugs. Study authors wrote that, “individuals infected with the HPV...reported a safe decrease in their symptoms following treatment with Gene-Eden-VIR.” (3) The study authors also wrote that “we observed a statistically significant decrease in the severity, duration, and frequency of symptoms.” (4)

Both products can be ordered online on the Novirin and Gene-Eden-VIR websites, here:

<http://www.gene-eden-vir.com>

and

<http://www.novirin.com>

Novirin and Gene-Eden-VIR are natural antiviral dietary supplements. Their formula contains five natural ingredients: Selenium, Camellia Sinesis Extract, Quercetin, Cinnamomum Extract, and Licorice Extract. The first ingredient is a trace element, and the other four are plant extracts. Each ingredient and its dose was chosen through a scientific approach. Scientists at polyDNA, the company that invented and patented the formula, scanned thousands of scientific and medical papers published in various medical and scientific journals, and identified the safest and most effective natural ingredients against latent viruses.

To date, Novirin and Gene-Eden-VIR are the only natural antiviral products on the market with published clinical studies that support their claims. Note: Novirin has the same formula as Gene-Eden-VIR. However, it contains higher quality and more expensive ingredients.

Doctors can view the papers on Gene-Eden-VIR here:

<http://www.scirp.org/journal/PaperInformation.aspx?PaperID=36101>

http://www.scirp.org/journal/PaperInformation.aspx?PaperID=44234#.VIBA_NKUf90

Are there other treatments or remedies available against the HPV?

“There are no drugs approved against the HPV. Current treatments include procedures, such as cryotherapy, conization, and the Loop Electrosurgical Excision Procedure (LEEP). These procedures use liquid nitrogen, a surgical knife (scalpel), a carbon dioxide (CO2) laser, or electrical current to remove the abnormal growths caused by the HPV. These growths include cells that harbor the active virus (this is before the HPV has caused cancer). The procedures do not target cells with the latent virus. Since they do not remove the latent virus, these procedures only produce a temporary remission.” (3) In contrast, the formula of Novirin and Gene-Eden-VIR was shown to reduce HPV symptoms in two separate post-marketing clinical studies that followed FDA guidelines.

All orders of these products are completely confidential, and no information is shared or sold to any third party. Privacy is assured.

Reference:

(1) Cote, R. "Campaign For HPV Vaccine Requirement May Have Been Hasty, Backfired" Published July 14, 2015 Jezebel.com

(2) Macrae, F. "Tens of thousands of teenage girls believed to have fallen ill with debilitating illnesses after routine HPV cervical cancer jab." Last updated June 1, 2015. Mail Online
<http://www.dailymail.co.uk/health/article-3104629/Tens-thousands-teenage-girls-fall-ill-debilitating-illnesses-routine-HPV-cervical-cancer-jab.html>

(3) Siegel-Itzkovich, J. "HPV: To vaccinate or not to vaccinate." Published September 21, 2013.
<http://www.jpost.com/Health-and-Science/HPV-To-vaccinate-or-not-to-vaccinate-326711>

(4) Polansky H, Itzkovitz E. Gene-Eden-VIR Is Antiviral: Results of a Post Marketing Clinical Study. Pharmacology & Pharmacy, 2013, 4, 1-8
<http://www.scirp.org/journal/PaperInformation.aspx?PaperID=36101>

Greg Bennett



CBCD
585-250-9999
email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2015 IPD Group, Inc. All Right Reserved.

